SCHEMBL2335237

SCHEMBL2335237

CCNc1ccc(NC(C)=O)cc1/N=C1\S/C(=C2\Sc3ccccc3N2C)C(=O)N1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 7/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 5/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 6/20 0.39
TP53 P04637 5/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ESR2 Q92731 1/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD4 O60885 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
GAA P10253 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NOX1 Q9Y5S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2335242 1.00 KMT2A (0.42) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2342529 0.94 KMT2A (0.43) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2342527 0.94 KMT2A (0.43) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2333127 0.92 KMT2A (0.41) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2333130 0.92 KMT2A (0.41) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2336197 0.91 KMT2A (0.40) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2336193 0.91 KMT2A (0.40) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2334965 0.91 KMT2A (0.43) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2334960 0.91 KMT2A (0.43) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL2335303 0.91 KMT2A (0.39) KMT2AL3MBTL1MEN1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465882-B1 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-08-24 EP disclosed
US-7115640-B2 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. (US) 2006-10-03 US disclosed
US-20040180942-A1 Heterocyclic modulators of nuclear receptors X-CEPTOR THERAPEUTICS, INC. 2004-09-16 US disclosed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180942-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 KMT2A 2838/4885L3MBTL1 3584/4885MEN1 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.